Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

Status Completed

Clinical Trial Summary

The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.

Clinical Trial Description

Glaucoma is a disease characterized by optic nerve damage, visual field defects, elevated intraocular pressure (IOP) and progressive vision loss. More than 3 million Americans have glaucoma and more than 150,000 are blind as a result.

Regular use of glaucoma medications can usually lower intraocular pressure (IOP), prevent disease progression, preserve vision and prevent blindness. However, many people with glaucoma do not always use their medication as directed, with about one-third to one-half of patients with glaucoma not taking their drops as often as necessary, or have difficulty putting in the drops. There are also numerous local side effects from using glaucoma eye drops including red eyes, blurry vision and dry eye symptoms. Systemic side effects from eye drops range from triggering asthma, to lethargy and depression.

Selective laser trabeculoplasty (SLT) has been used safely and effectively for the treatment of elevated IOP in patients with open angle glaucoma for more than 20 years. SLT may result in mild and temporary IOP elevation, but this is a small risk and rarely significant. Other side effects include blurred vison and inflammation of the cornea (front, clear part of the eye), but they are extremely rare.

The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be considered as first glaucoma treatment before the use of glaucoma eye drops. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03365778
Study type	Interventional
Source	Wills Eye
Contact
Status	Completed
Phase	N/A
Start date	October 23, 2017
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01841437` - Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry	N/A
Completed	`NCT02077231` - Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients	N/A
Completed	`NCT01410188` - Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension	Phase 1/Phase 2
Recruiting	`NCT05557058` - GORE Glaucoma Drainage Implant Clinical Study	N/A
Not yet recruiting	`NCT03924544` - Decorin in Sub Scleral Trabeculectomy	Phase 1
Active, not recruiting	`NCT03673644` - Impact of Glaucoma and Visual Field Loss on Life Space
Completed	`NCT01915940` - Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension	Phase 2
Completed	`NCT03889652` - Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
Terminated	`NCT03273907` - Post Approval Study of the CyPass System	N/A
Recruiting	`NCT03193333` - PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)	Phase 3
Recruiting	`NCT03921931` - Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study	N/A
Not yet recruiting	`NCT04609345` - Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Recruiting	`NCT05264818` - Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Completed	`NCT04333433` - PRESERFLO® MicroShunt Extension Study
Enrolling by invitation	`NCT02144103` - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration	Phase 1/Phase 2
Completed	`NCT01281020` - Adherence With Fixed Versus Unfixed Glaucoma Therapy
Recruiting	`NCT04891588` - Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD	N/A
Completed	`NCT03145129` - PAIR Study-PAP And IOP Relationship: Study 2
Completed	`NCT03104621` - Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients	Phase 4
Completed	`NCT01528111` - Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension	Phase 1/Phase 2